

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

1 / 36




FIG. 1



USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

2 / 36






FIG. 2



USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030CI

4 / 36




FIG. 4

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030CI

5 / 36




FIG. 5

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

6 / 36

ANTI-MUC18 ANTIBODY C3.19.1

Nucleotide Sequence of Heavy Chain Variable Region

5' -

CAGGTGCAGCTGCAGGAGTCGGGCCAGGACTGGTGAAGCCTCGGAGACCCTGTCCTCACCTGC
ACTGTCTCTGGTGGCTCCATCAGTAGTTACTACTGGAGCTGGATCCGGCAGCCCCAGGGAAGGGA
CTGGAGTGGATTGGCTATATCTATTACACTGGACCTCCAACTACAACCCCTCCCTCAAGAGTCGC
GTCACCATATCAGTGGACACGTCCAAAAACAGTTCTCCCTGAGGCTGAGTTCTGTGACCGCTGCG
GACACGGCCGTTTATTACTGTGCGAGAGATCAGGGCAGTGGTTACTACCCGATGCTTTGATATC
TGGGGCCAAGGGACAATGGTCACCGTCTTCAG 3' (SEQ ID NO: 3)

Amino Acid Sequence of Heavy Chain Variable Region

QVQLQESGPGLVKPSETSLTCTVSGGSISYYWSWIRQPPGKGLEWIGYIYYTWTSNYNPSLKS
VTISVDTSKNQFSRLSSVTAADTAVYYCARDQGQWLLPDAFDIWGQGTMVTVSS (SEQ ID NO:1)

Nucleotide Sequence of Light Chain Variable Region

5' -

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCGTACCCCTGGAGAGCCGGCCTCCATCTCC
TGCAGGTCTAGTCAGAGCCTCCTGCGTAGTAATGGATACAACATTGGATTGGTACCTGCAGAAG
CCAGGACAGTCTCCACATCTCCTGATCTATTGGTTCTAATCGGGCTCCGGGGTCCCTGACAGG
TTCAGTGGCAGTGGATCAGGCACAGATTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTT
GGGGTTTATTACTGCATGCAAGCTAACAAAGTCCGATCACCTCGGCCAAGGGACACGACTGGAG
ATTAAAC 3' (SEQ ID NO: 4)

Amino Acid Sequence of Light Chain Variable Region

DIVMTQSPLSLPVTPGEPASISCRSSQSLLRSNGNYLDWYLQKPGQSPHLLIYLGSNRASGV
PDR FSGSGSGTDFTLKISRVEADVGVYYCMQAQQSPITFGQGTRLEIK (SEQ ID NO: 2)

FIG. 6

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

7 / 36

ANTI-MUC18 ANTIBODY C6.11.13

Nucleotide Sequence of Heavy Chain Variable Region

5' -

CAGGTGCAGCTGCAGGAGTCGGGCCAGGACTGGTGAAGCCTCACAGACCTGTCCTCACCTGC
ACTGTCTCTGGTGGCTCCATCAGCAGTGGTACTTACCACTGGAGCTGGATCCGCCAGCACCCAGGG
AAGGGCCTGGAGTGGATTGGGTACATCTATTACAGTGGAGCACCTACTACAACCCGTCCCTCAAG
AGTCGAGTTACCATATCAGTAGACACGTCTAAGAACAGTTCTCCCTGAAGCTGAGCTGTGACT
GCCGC GGACACGCCGTGTATTACTGTGCAGAGGGGGAGATGGCTACAAGTACTGGGCCAGGGA
ACCCTGGTCACCGTCTCCTCAG-3' (SEQ ID NO: 7)

Amino Acid Sequence of Heavy Chain Variable Region

QVLOQESGPGLVKPSQTLSLTCTVSGGSISSGTYHWSWIROHPGKGLEWIGYIYYSGSTYYNPSLK
SRVTISVDTSKNQFSLKLSSVTAADTAVYYCARGGDGYKYWGQGTLTVSS (SEQ ID NO: 5)

Nucleotide Sequence of Light Chain Variable Region

5'

GAAATAGTGATGACGCAGTCTCCAGCCACCCGTCTGTCTCCAGGGGAAAGAGGCCACCCCTCTCC
TGCAGGGCCAGTCAGAGTGTAGCAACAACTTAGCCTGGTATCAGCAGAAACCTGGCCAGGCTCCC
AGGCTCCTCATCTATGGTGCATCCACCAGGGCACTGGTATCCCAGCCAGGTTCACTGGCAGTGGG
TCTGGGACAGAGTTCACTCTCACCACAGCAGCCTGCAGTCTGAAGATTTGCAGTTATTACTGT
CAGCAGTATAATAACTGGCCTCGGACGTTGGCCAAGGGACCAAGGTGGAAATCAAAC 3'
(SEQ ID NO: 8)

Amino Acid Sequence of Light Chain Variable Region

EIVMTQSPATLSVSPGERATLSCRASQSVNNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSG
SGTEFTLTISLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK (SEQ ID NO: 6)

FIG. 7

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

8 / 36

ANTI-MUC18 ANTIBODY C3.10

Nucleotide Sequence of Heavy Chain Variable Region

1 CAGGTGCAGC TGCAGGAGTC GGGCCAGGA CTGGTGAAGC CTTCGGAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGT AGTTACTACT GGAGCTGGAT CCGGCAGGCC
121 CCAGGGAAAGG GACTGGAGTG GATTGGCTAT ATCTATTACA CTTGGACCAC CAACTACAAAC
181 CCCTCCCTCA AGAGTCGCGT CACCATATCA GTGGACACGT CCAAGAACCA GTTCTCCCTG
241 AGGCTGAGCT CTGTGACCGC TGCGGACACG GCCCTTTATT ACTGTGCGAG AGATCAGGGG
301 CAGTGGTTAC TACCCGATGC TTTTGATATC TGGGGCCAAG GGACAATGGT CACCGTCTCT
361 TCAG (SEQ ID NO: 11)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLQESGPG LVKPSETLSL TCTVSGGSIS SYYWSWIRQP PGKGLEWIGY IYYTWTTNYN
61 PSLKSRVTIS VDTSKNQFSL RLSSVTAADT ALYYCARDQG QWLLPDAFDI WGQGTMVTVS
121 S (SEQ ID NO: 9)

Nucleotide Sequence of Light Chain Variable Region

1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCAAGTCA GAGCATTAGC AACTATTAA ATTGGTATCA GCAGAAACCA
121 GGAAAAGCCC CTAAGCTCCT GATCTATGGT GCATCCAGTT TGCAAAGTGG GGTCCCATCA
181 AGGTTCAGTG GCAGTGGATC TGGGACAGAT TTCACTCTCA CCATCAGCAG TCTGCAACCT
241 GAAGATTTG CAACCTACTA CTGTCGACAG AGTTACAGTA CCCCTCCGGA GTGCAGTTT
301 GGCCAGGGGA CCAAGCTGGA GATCAAAC (SEQ ID NO: 12)

Amino Acid Sequence of Light Chain Variable Region

1 DIQMTQSPSS LSASVGDRVT ITCRASQSIS NYLNWYQQKP GKAPKLLIYG ASSLQSGVPS
61 RFSGSGSGTD FTLTISSLQP EDFATYYCRQ SYSTPPECSF GQGTKLEIK (SEQ ID NO:10)

FIG. 8

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

9 / 36

ANTI-MUC18 ANTIBODY C3.22

Nucleotide Sequence of Heavy Chain Variable Region

1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CTTCACAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGC AGTGGTGGTT ACTACTGGAC TTGGATCCGC
121 CAGCACCCAG GGAAGGGCCT GGAGTGGATT GGGTTCATCT ATTACAGTGG GAGCACCTAC
181 TACAACCCGT CCCTCAAGAG TCGAGTTACC ATATCAGTAG ACACGTCTAA GAACCAGTTC
241 TCCCTGAAGC TGAGCTCTGT GACTGCCGCG GACACGCCG TGTATTACTG TGCGAGAGAG
301 GGAGATGGCT TTGACTACTG GGGCCAGGGA ACCCTGGTCA CCGTCTCCTC AG
(SEQ ID NO: 15)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLOQESGPG LVKPSQTL SL TCTVSGGSIS SGGYYWTWIR QHPGKGLEWI GFIYYSGSTY
61 YNPSLKSRTV ISVDTSKNQF SLKLSSVTAA DTAVYYCARE GDGF DYWGQG TLTVVSS
(SEQ ID NO: 13)

Nucleotide Sequence of Light Chain Variable Region

1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCAAGTCA GGGCATTAGA AATGATTTAG GCTGGTATCA GCAGAAACCA
121 GGGAAAGCCC CTAAGCGCCT GATCTATGCT GCATCCAGTT TGCAAAGTGG GGTCCCATCA
181 AGGTTCAGCG GCAGTGGATC TGGGACAGAA TTCACTCTCA CAATCAGCAG CCTGCAGCCT
241 GAAGATTTG CAACTTATTA CTGTCTACAG CATAATAGTT ACCCGCTCAC TTTCGGCGGA
301 GGGACCAAGG TGGAGATCAA AC (SEQ ID NO: 16)

Amino Acid Sequence of Light Chain Variable Region

1 DIQMTQSPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKRLIYA ASSLQSGVPS
61 RFSGSGSGTE FTLTISLQP EDFATYYCLQ HNSYPLTFGG GTKVEIK (SEQ ID NO: 14)

FIG. 9

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

10 / 36

ANTI-MUC18 ANTIBODY C3.27

Nucleotide Sequence of Heavy Chain Variable Region

1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CTTCGGAGAC CCTGTCCCTC
61 ACCTGCACTG TCTCTGGTGG CTCCATCAGT AGTTACTACT GGAGCTGGAT CCGGCAGCCC
121 CCAGGGAAGG GACTGGAGTG GATTGGCTAT ATCTATTACA CTTGGACCTC CAACTACAAC
181 CCCTCCCTCA AGAGTCGCGT CACCATATCA GTGGACACGT CCAAGAACCA GTTCTCCCTG
241 AGGCTGAGTT CTGTGACCGC TGCGGACACG GCCGTTACT ACTGTGCGAG AGATCAGGGG
301 CAGTGGTTAC TACCCGATGC TTTTGATATC TGGGGCCAAG GGACAATGGT CACCGTCTCT
361 TCAG (SEQ ID NO: 19)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLQESGPG LVKPSETLSL TCTVSGGSIS SYYWSWIRQP PGKGLEWIGY IYYTWTNSYN
61 PSLKSRVTIS VDTSKNQFSL RLSSVTAADT AVYYCARDQG QWLLPDAFDI WGQGTMVTVS
121 S (SEQ ID NO: 17)

Nucleotide Sequence of Light Chain Variable Region

1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCAAGTCA GGGCATTAGA AATGATTAG GCTGGTATCA GCAGAAACCA
121 GGGAAAGCCC CTAAGCGCCT GATCTATGCT GCATCCAGTT TGCAAAGTGG GGTCCCATCA
181 AGGTTCAGCG GCAGTGGATC TGGGACAGAG TTCACTCTCA CAATCAGCAG CCTGCAGCCT
241 GAAGATTTG CAACTTATTA CTGTCTACAG CATAATAGTT ACCCGTGGAC GTTCGGCCAA
301 GGGACCAAGG TGGAAATCAA AC (SEQ ID NO: 20)

Amino Acid Sequence of Light Chain Variable Region

1 DIQMTQSPSS LSASVGDRVT ITCRASQGIR NDLGWYQQKP GKAPKRLIYA ASSLQSGVPS
61 RFSGSGSGTE FTLTISSLQP EDFATYYCLQ HNSYPWTFGQ GTKVEIK
(SEQ ID NO: 18)

FIG. 10

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

11 / 36

ANTI-MUC18 ANTIBODY C3.45

Nucleotide Sequence of Heavy Chain Variable Region

1 CAGGTTCAGC TGGTGCAGTC GGGAGCTGAG GTGAAGAAC CTGGGGCCTC AGTGAAGGTC
61 TCCTGCAAGG CTTCTGGTTA CACCTTTTT AGCTATGGTT TCAGCTGGGT GCGACAGGCC
121 CCTGGACAAG GGCTTGAGTG GCTGGGATGG ATCAGCGCTT ACAATGGTAA CACAAACTAT
181 GCACAGAAC C TCCAGGGCAG AGTCACCATG ACCACAGACA CTTCCACGAG CACAGCCTAC
241 ATGGAGCTGA GGAGCCTGAG ATCTGACGAC ACGGCCGTGT ATTACTGTGC GAGAGAAACT
301 AAGGTTCGGG GAGTCCACTA CTACGGTATG GACGTCTGGG GCCAAGGGAC CACGGTCACC
361 GTCTCCTCAG (SEQ ID NO: 23)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLVQSGAE VKKPGASVKV SCKASGYTFF SYGFSWRQAA PGQGLEWLWV ISAYNGNTNY
61 AQKLQGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARET KVRGVHYYGM DVWGQGTTVT
121 VSS (SEQ ID NO: 21)

Nucleotide Sequence of Light Chain Variable Region

1 DIVMTQSPDLS AVSLGERAT IICKSSQSIL YSSNNKNYLG WYQQKPGQPP KLLIYWA STR
61 ESGVPARFSG SGSGTDFLT INSLQAEDVA VYYCQQYYST PRSFGQGTMV EIK (SEQ ID
NO: 24)

Amino Acid Sequence of Light Chain Variable Region

1 GACATCGTGA TGACCCAGTC TCCAGACTCC CTGGCTGTGT CTCTGGGCCA GAGGGCCACC
61 ATCATCTGCA AGTCAGGCCA GAGTATTTA TACAGCTCCA ACAATAAGAA CTACTTAGGT
121 TGGTACCAGC AGAAACCAGG ACAGCCTCCT AAGCTGCTCA TTTACTGGGC ATCTACCCGG
181 GAATCCGGGG TCCCTGCCCG ATTCAAGTGGC AGCGGGTCTG GGACAGATT CACTCTCACC
241 ATCAAACAGGCC TGCAGGGCTGA AGATGTGGCA GTTTATTACT GTCAGCAATA TTATAGTACT
301 CCTCGGTCGT TCGGCCAAGG GACCATGGTG GAAATCAAAC (SEQ ID NO 22)

FIG. 11

ANTI-MUC18 ANTIBODY C3.65**Nucleotide Sequence of Heavy Chain Variable Region**

1 CAGGTGCAGC TGCAGGAGTC GGGCCCAGGA CTGGTGAAGC CTTCACAGAC CCTGTCCCTC
 61 ACCTGCACTG TCTCTGGTGG CTCCATCAAC AGTGGTGGTT GCTACTGGAG CTGGATCCGC
 121 CAGCACCCAG GGAAGGGCCT GGAGTGGATT GGGTACATCT ATTCCAGTGG GAGCACCTAC
 181 TACAACCCGT CCCTCAAGAG TCGAATTACC TTATCAGTAG ACACGTCTAA GAACCAGTTC
 241 TCCCTGAAGC TGAACCTAT GACTGCCGCG GACACGGCCG TGTATTACTG TGCGAGAGAT
 301 CGGGAAACAG CTGGTTTGA CTACTGGGGC CAGGGAACCC TGGTCACCGT CTCCTCAG
 (SEQ ID NO: 27)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLQESGPG LVKPSQTLSL TCTVSGGSIN SGGCYWSWIR QHPGKGLEWI GYIYSSGSTY
 61 YNPSLKSRII LSVDTSKNQF SLKLNSMTAA DTAVYYCARD RETAGFDYWG QGTLVTVSS
 (SEQ ID NO: 25)

Nucleotide Sequence of Light Chain Variable Region

1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
 61 ATCACTTGCC AGGCGAGTCA GGACATTAAC AACTATTAA ATTGGTATCA GCAGAAACCA
 121 GGGAAAGCCC CTAAGCTCCT GATCTACGAT GCATCCAATT TGGAAACAGG GGTCCCATCA
 181 AGGTTCAGTG GAAGTGGATC TGGGACAGAT TTTACTTTCA CCATCAGCGG CCTGCAGCCT
 241 GAGGATATTG CAACATATTA CTGTCAACAG TATGATACTC TCCCTCTCAC TTTCGGCGGC
 301 GGGACCAAGG TGGAGATCAA AC (SEQ ID NO: 28)

Amino Acid Sequence of Light Chain Variable Region

1 DIQMTQSPSS LSASVGDRVT ITCQASQDIN NYLNWYQQKP GKAPKLLIYD ASNLETGVPS
 61 RFSGSGSGTD FTFTISGLQP EDIATYYCQQ YDTLPLTFGG GTKVEIK (SEQ ID NO: 26)

FIG. 12

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

13 / 36

ANTI-MUC18 ANTIBODY C6.1

Nucleotide Sequence of Heavy Chain Variable Region

1 CAGGTGCAGC TGGTGGAGTC GGGGGGAGGC GTGGTCCAGC CTGGGAGGTC CCTGAGACTC
61 TCCTGTGCAG CCTCTGGATT CACCTTCAGT AGCTATGCCA TGCACTGGGT CCGCCAGGCT
121 CCAGGCAAGG GGCTGGAGTG GGTGGCAGTT ATATCATATG ATGGAAGTAA TAAATACTAT
181 GCAGACTCCG TGAAGGGCCG ATTCAACCATC TCCAGAGACA ATTCCAAGAA CACGCTGTAT
241 CTGCAAATGA ACAGCCTGAG AGCTGAGGAC ACGGCTGTGT ATTACTGTGC GAGATCGATT
301 TTTGGAGTGG TTATCGACTA CGGTATGGAC GTCTGGGCC AAGGGACCAC GGTACCCGTC
361 TCCTCAG (SEQ ID NO: 31)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVOLVESGGG VVQPGRLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV ISYDGSNKYY
61 ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSF FGVVIDYGMV VWGQGTTVTV
121 SS (SEQ ID NO: 29)

Nucleotide Sequence of Light Chain Variable Region

1 GACATCCAGA TGACCCAGTC TCCATCCTCC CTGTCTGCAT CTGTAGGAGA CAGAGTCACC
61 ATCACTTGCC GGGCGAGTCA GGGCATTAGA AATTATTTAG CCTGGTATCA GCAGAAATCCA
121 GGGAAAGTTC CTAAGCTCCT GATCTATGGT GCATCCACTT TGCAATCAGG GGTCCCATCT
181 CGGTTCACTG GCAGTGGATC TGGGACAGAT TTCACTCTCA CCATCAGCAG CCTGCAGCCT
241 GAAGATGTTG CAACTTATTA CTGTCAAAAG TTTAGCAGTC CCCCATTAC TTTCGGCCCT
301 GGGACCAAAG TGGATATCAG TC (SEQ ID NO: 32)

Amino Acid Sequence of Light Chain Variable Region

1 DIQMTQSPSS LSASVGDRVT ITCRASQGIR NYLAWYQQNP GKVPKLLIYG ASTLQSGVPS
61 RFSGSGSGTD FTLTSSLQP EDVATYYCQK FSSPPFTFGP GTKVDIS (SEQ ID NO: 30)

FIG. 13

ANTI-MUC18 ANTIBODY C6.9**Nucleotide Sequence of Heavy Chain Variable Region**

1 CAGGTGCAGC TGGAGCAGTC GGGGCCAGGA CTGGTGAAGC CTTCAGAGAC CCTGTCCCTC
 61 ACCTGCACTG TCTCTGGTGG CTCCATCAGC AGTGGTACTT ACCACTGGAG CTGGATCCGC
 121 CAGCACCCAG GGAGGGGCCT GGAGTGGATT GGATACATCT ATTACAGTGG GAGCACCTAC
 181 CACAACCCGT CCCTCAAGAG TCGAATTACC ATATCAGTAG ACACGTCTAA GAACCAAGTTC
 241 TCCCTGAAGC TGAGCTCTGT GACGGCCGCG GACACGGCCG TGTATTACTG TGCAGAGAGGG
 301 GGAGATGGCT ACAGATACTG GGGCCAGGGA ACCCTGGTCA CCGTCTCCTC AG
 (SEQ ID NO: 35)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLEQSGPG LVKPSETLSL TCTVSGGSIS SGTYHWSWIR QHPGRGLEWI GYIYYSGSTY
 61 HNPSLKSRIIT ISVDTSKNQF SLKLSSVTAA DTAVYYCARG GDGYRYWGQG TLTVVSS
 (SEQ ID NO: 33)

Nucleotide Sequence of Light Chain Variable Region

1 GAAATAGTGA TGACGCAGTC TCCAGCCACC CTGTCTGTGT CTCCAGGGGA AAGAGCCACC
 61 CTCTCCTGCA GGGCCAGTCA GAGTATTAGC AACAACTTCG CCTGGTACCA GCAGAAACCT
 121 GGCCAGGCTC CCAGGCTCCT CATCTTGTT GCATCCACCA GGGCCACTGG TATCCCAGCC
 181 AGGTTCAGTG GCAGTGGGTC TGGGACAGAA TTCACTCTCA CCATCAGCAG CCTACAGTCT
 241 GAAGATTTG CAGTTTATTA CTGTCAGCAG TATAATAACT GCCCTCGGAC GTTCGGCCAA
 301 GGGACCAAGG TGGAAATCAA AC (SEQ ID NO: 36)

Amino Acid Sequence of Light Chain Variable Region

1 EIVMTQSPAT LSVSPGERAT LSCRASQSIS NNFAWYQQKP GQAPRLLIFG ASTRATGIPA
 61 RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPRTFGQ GTKVEIK (SEQ ID NO: 34)

FIG. 14

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

15 / 36

ANTI-MUC18 ANTIBODY C6.2

Nucleotide Sequence of Heavy Chain Variable Region

1 CAGGTGCAGC TGCAGGAGTC GGGCCAGGA CTGGTGAAGC CCTCGGAGAC CCTGTCCCTC
61 ACCTGCAGTG TCTCTGGTGG CTCCATCAGT ACTTACTACT GGAGTTGGAT CCGGCAGGCC
121 CCAGGGAAAGG GACTGGAGTG GATTGGATAC ATCTATTACA CTGGGAACAC CTACTACAAAC
181 CCCTCCCTCA AGAGTCGAGT CACCGTTCA GTTGACACGT CCAAGAACCA GTTCTCCCTG
241 AAGCTGAACCTCTGTGACCGC TGCGGACACG GCCGTGTATT ACTGTGCGAG AGATCCAGGC
301 CAGTGGCTGG TCCCTGATGC TTTTGATATC TGGGGCCAAG GGACAATGGT CTCCGTCTCT
361 TCAG (SEQ ID NO: 39)

Amino Acid Sequence of Heavy Chain Variable Region

1 QVQLQESGPG LVKPSETLSL TCTVSGGSIS TYYWSWIROQ PGKGLEWIGY IYYTGNTYYN
61 PSLKSRVTVS VDTSKNQFSL KLNSVTAADT AVYYCARDPG QWLVPDAFDI WGQGTMVSVS
121 S (SEQ ID NO: 37)

Nucleotide Sequence of Light Chain Variable Region

1 GATATTGTGA TGACTCAGTC TCCACTCTCC CTGCCGTCA TTCCTGGAGA GCCGGCCTCC
61 ATCTCCTGCA GGTCTAGTCA GAGCCTCCTG CAGAGTAATG GAAACAACTA TTTGGATTGG
121 TACCTGCAGA AGCCAGGGCA GTCTCCACAG CTCCTGATCT ATTGGGGTTC TAATCGGGCC
181 TCCGGGGTCC CTGACAGGTT CAGTGGCAGT GGATCAGGCA CAGATTTAC ACTGAAAATC
241 AGCAGAGTGG AGGCTGACGA TGTTGGGATT TATTACTGCA TGCAAGCTCT CCAAATTCC
301 CTCACTTTCG GCGGAGGGAC CAAGGTGGAG ATCAAAC (SEQ ID NO: 40)

Amino Acid Sequence of Light Chain Variable Region

1 DIVMTQSPLS LPVIPGEPAS ISCRSSQSLL QSNGNNYLDW YLQKPGQSPQ LLIYLGSNRA
61 SGVPDRFSGS GSGTDFTLKI SRVEADDVGI YYCMQALQIP LTFGGGTKVE IK
(SEQ ID NO: 38)

FIG. 15

		Section 1			
		10	20	30	40
A15-3.10	HC	(1) QVQESGPGLVVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYY			
VH4-59		(1) QVQESGPGLVVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYY			
Consensus		(1) QVQLQESGPGLVVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGYIYY			
		Section 2			
		50	60	70	80
A15-3.10	HC	(54) STNYNPSI	WTKSRVTISVDTSRNQFS14P1	LISSVTAADTANYYCAR	
VH4-59		(54) STNYNPSI	WTKSRVTISVDTSRNQFS14P1	LISSVTAADTANYYCAR	
Consensus		(54) S	STNYNPSI	WTKSRVTISVDTSRNQFS14P1	LISSVTAADTANYYCAR
		Section 3			
		107	121		
A15-3.10	HC	(107) AFDIWGQGTMVTVSS			
VH4-59		(98) -----			
Consensus		(107)			

positives: 79.3%	identity: 76.0%
------------------	-----------------

FIG. 16

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

17 / 36

		Section 1			Section 2			Section 3		
A15-3.10_LC	(1)	1	10	20	30	40	50	53		
O2	(1)	DIQMTQSPSSLSASVGDRVTITCRASQTSISNYLNWYQQKPGKAPKLLIYGAASS								
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQTSISYYLNWYQQKPGKAPKLLIYGAASS								
A15-3.10_LC	(54)	54	60	70	80	90	99	106		
O2	(54)	LQSGVPSRFSGSGSGTDFLTITISSLQPEDFATYYCROSYSTPPECSFGQGTLI								
Consensus	(54)	LQSGVPSRFSGSGSGTDFLTITISSLQPEDFATYYCQSYSTPQSYSTP								
A15-3.10_LC	(107)	107								
O2	(107)	EIK								
Consensus	(96)	---								

positives: 85.3%	identity: 84.4%
------------------	-----------------

FIG. 17

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030CI

18 / 36

		Section 1			Section 2			Section 3		
		1	10	20	30	40	53			
A15-3.22	HC	(1)	QVQESGPGLVVKPSQTLISLTCTVSGGSISSGGYWTWIRQHPGKGLENTIGFV							
VH4-31		(1)	QVQESGPGLVVKPSQTLISLTCTVSGGSISSGGYWTWIRQHPGKGLENTIGFV							
Consensus		(1)	QVQESGPGLVVKPSQTLISLTCTVSGGSISSGGYWTWIRQHPGKGLENTIGFV							
		54	60	70	80	90	90			
A15-3.22	HC	(54)	YYSGSTYYNPSLKSRTVTTSVVDTTSKNQFSLKLSSVTAADTAVYYCAR							
VH4-31		(54)	YYSGSTYYNPSLKSRTVTTSVVDTTSKNQFSLKLSSVTAADTAVYYCAR							
Consensus		(54)	YYSGSTYYNPSLKSRTVTTSVVDTTSKNQFSLKLSSVTAADTAVYYCAR							

positives: 84.6%	identity: 82.9%
------------------	-----------------

FIG. 18

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABCENIX.030C1

19 / 36

Section 1					
	1	10	20	30	40
A15-3.22_LC	(1) DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKR				53
A30	(1) DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKR				
Consensus	(1) DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKR				

Section 2					
	54	60	70	80	90
A15-3.22_LC	(54) LQSGVPSRFSGSGSGTEFTLTISSLOPEDFATYYCLQHNSYP				
A30	(54) LQSGVPSRFSGSGSGTEFTLTISSLOPEDFATYYCLQHNSYP				
Consensus	(54) LQSGVPSRFSGSGSGTEFTLTISSLOPEDFATYYCLQHNSYP				

Section 3					
	107	107			
A15-3.22_LC	(107) K				
A30	(96) -				
Consensus	(107)				

positives: 88.8% | identity: 88.8%

FIG. 19

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

20 / 36

	Section 1			
A15-3.27 HC	(1) 1	10	20	30 40 53
VH4-59	(1) QVQLQESGPGLVVKPSETLSLTCTVSGGSTISSYYWNWIROPPGKGLEWIGIYY			
Consensus	(1) QVQLQESGPGLVVKPSETLSLTCTVSGGSTISSYYWNWIROPPGKGLEWIGIYY			
	Section 2			
A15-3.27 HC	(54) 54	60	70	80 90 106 106
VH4-59	(54) WTSNNYNPSLKSRTVTISVDTSKNQFSIPLSSSVTAADTAVYYCAR			
Consensus	(54) SGSTTNNYNPSLKSRTVTISVDTSKNQFSIPLSSSVTAADTAVYYCAR			
	Section 3			
A15-3.27 HC	(107) 107	121		
VH4-59	(107) AFDIWGQGTMVTVSS			
Consensus	(98) -----			

positives: 79.3% | identity: 76.0%

FIG. 20

		Section 1			Section 2			Section 3		
		10	20	30	40	50	60	70	80	90
A15-3.27	LC	(1) <u>DIQMTQSPSSLSASVGDRVTTITCRASQGIRNDLGWYQQKPGKAPKR</u> LIYAASS								
	A30	(1) <u>DIQMTQSPSSLSASVGDRVTTITCRASQGIRNDLGWYQQKPGKAPKR</u> LIYAASS								
Consensus		(1) DIQMTQSPSSLSASVGDRVTTITCRASQGIRNDLGWYQQKPGKAPKR	LIYAASS							
		53	53	53	53	53	53	53	53	53
A15-3.27	LC	(54) <u>LQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYP</u>								
	A30	(54) <u>LQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYP</u>								
Consensus		(54) LQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYP								
		106	106	106	106	106	106	106	106	106

positives: 88.8%	identity: 88.8%
------------------	-----------------

FIG. 21

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030CI

22 / 36

		Section 1			
		10	20	30	40
A15-3.45	HC	(1) QVQLVQSGAEVKKPGASVKKVSCAKASGYTFFSYGFISWYRQAPGQGLEWIGWISA			53
VH1-18		(1) QVQLVQSGAEVKKPGASVKKVSCAKASGYTFFSYGFISWYRQAPGQGLEWIGWISA			
Consensus		(1) QVQLVQSGAEVKKPGASVKKVSCAKASGYTFFSYGFISWYRQAPGQGLEWIGWISA			
		Section 2			
		60	70	80	90
A15-3.45	HC	(54) YNGNTNYAQQLQGRVTMTTDTSTAYMELRSIDLDTAVYYCARETKVRCGVH			106
VH1-18		(54) YNGNTNYAQQLQGRVTMTTDTSTAYMELRSIDLDTAVYYCARETKVRCGVH			
Consensus		(54) YNGNTNYAQQLQGRVTMTTDTSTAYMELRSIDLDTAVYYCARETKVRCGVH			
		Section 3			
		107	123		
A15-3.45	HC	(107) YYGMDVWGQGTTVTVSS			
VH1-18		(99) -----			
Consensus		(107) YYGMDVWGQGTTVTVSS			

positives: 78.0%	identity: 77.2%
------------------	-----------------

FIG. 22

		Section 1				Section 2				Section 3			
A15-3.45_LC	(1)	1	10	20	30	40	50						
B3	(1)	DIVMTQSPDSLAVSLGERATI	ICKSSQSTLYSSNNKNYL	GWYQQKPGQOPPKIL									
Consensus	(1)	DIVMTQSPDSLAVSLGERATI	ICKSSQSTLYSSNNKNYL	GWYQQKPGQOPPKIL									
A15-3.45_LC	(54)	54	60	70	80	90	106						
B3	(54)	TYWASTRESGVPARFSGSGT	DETTLTINSLQAE	DVAVYYCQQYYSTPRSF									
Consensus	(54)	TYWASTRESGVPDRESGSGT	DETTLTISLQAE	DVAVYYCQQYYSTP	-----								
A15-3.45_LC	(107)	107	113										
B3	(107)	GTMVEIK											
Consensus	(107)												

positives: 86.7%	identity: 85.0%
------------------	-----------------

FIG. 23

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

24 / 36

		Section 1			Section 2			Section 3		
A15-3.65 HC	(1) 1	10	20	30	40	50	60	70	80	90
VH4-31	(1) QVQLOQESGPGLVVKPSQTLSSLTCTVSGGSTI	QVQLOQESGPGLVVKPSQTLSSLTCTVSGGSTI								
Consensus	(1) QVQLQESGPGLVVKPSQTLSSLTCTVSGGSTI	QVQLQESGPGLVVKPSQTLSSLTCTVSGGSTI								
A15-3.65 HC	(54) 54	60	70	80	90	100	106			
VH4-31	(54) YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT	YSSGSTYYNPSLKSRLT
Consensus	(54) Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT	Y SGSTYYNPSLKSRLT

positives: 79.8% | identity: 77.3%

FIG. 24

		Section 1				
		10	20	30	40	53
A15-3.65_LC	(1)	DIQMTQSPSSLSASVGDRVTITCQASQDI		NNYLNWYQQKPGKAPKLIYDASN		
	(1)	DIQMTQSPSSLSASVGDRVTITCQASQDI		NNYLNWYQQKPGKAPKLIYDASN		
O8	(1)	DIQMTQSPSSLSASVGDRVTITCQASQDI		NNYLNWYQQKPGKAPKLIYDASN		
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCQASQDI		NNYLNWYQQKPGKAPKLIYDASN		
		Section 2				
		54	60	70	80	90
A15-3.65_LC	(54)	LETGVPSRFSQSGSGT	DFFTFTIS	GLQPEDIATYYCQQYDTHPLT	FGGGTKVEI	
	(54)	LETGVPSRFSQSGSGT	DFFTFTIS	GLQPEDIATYYCQQYDTHPLT	FGGGTKVEI	
O8	(54)	LETGVPSRFSQSGSGT	DFFTFTIS	GLQPEDIATYYCQQYDTHPLT	FGGGTKVEI	
Consensus	(54)	LETGVPSRFSQSGSGT	DFFTFTIS	GLQPEDIATYYCQQYDTHPLT	FGGGTKVEI	
		Section 3				
		107	107			
A15-3.65_LC	(107)	K				
	(107)	K				
O8	(96)	-				
Consensus	(107)					

positives: 86.0%	identity: 86.0%
------------------	-----------------

FIG. 25

		Section 1			
		10	20	30	40
A15-6.1 HC	(1)	QVQLVE SGGSV VQPGRSI RLSCAASGFTFSSYAMH WVRQAPGKGLEWVA VTSY			
VH3-30	(1)	QVQLVE SGGSV VQPGRSI RLSCAASGFTFSSYAMH WVRQAPGKGLEWVA VTSY			
Consensus	(1)	QVQLVE SGGVVQPGRSI RLSCAASGFTFSSYAMH WVRQAPGKGLEWVA VTSY			
		Section 2			
		54	60	70	80
A15-6.1 HC	(54)	DGSNKYYADSVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAR			
VH3-30	(54)	DGSNKYYADSVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAR			
Consensus	(54)	DGSNKYYADSVKGRFTISRDNSKNTLYLQMN SLRAEDTAVYYCAR			
		Section 3			
		107	122		
A15-6.1 HC	(107)	YGMIDVW GQGTTVTVSS			
VH3-30	(99)				
Consensus	(107)				

positives: 80.3%	identity: 79.5%
------------------	-----------------

FIG. 26

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

27 / 36

		Section 1															
		1	10	20	30	40	54	Section 2									
A15-6.1	LC	(1)	DIQMTQSPSSLSASVGDRVITITCRASQGI	RNYLAWYQQNPGKVPKLLIYGA													
A20		(1)	DIQMTQSPSSLSASVGDRVITITCRASQGI	SNYI	PGKVPKLLIYGA												
Consensus		(1)	DIQMTQSPSSLSASVGDRVITITCRASQGI	NYLAWYQQ	PGKVPKLLIYGA	STL											
		(55)	55	60	70	80	90	Section 2									
A15-6.1	LC	(55)	QSGVPSRFSGSGSGTDFITLTISSLOP	EDVATYYCQK	SSP												
A20		(55)	QSGVPSRFSGSGSGTDFITLTISSLOP	EDVATYYCQK	NSA												
Consensus		(55)	QSGVPSRFSGSGSGTDFITLTISSLOP	EDVATYYCQK	NSA												

positives: 85.0%	identity: 83.2%
------------------	-----------------

FIG. 27

positives: 81.2% | identity: 77.8%

FIG. 28

		Section 1			
		10	20	30	40
L2	(1) EIVMTQSPATLSVSPGERATLSCRASQSVSSN				53
A15-6.12_LC	(1) EIVMTQSPATLSVSPGERATLSCRASQSVSSN				
Consensus	(1) EIVMTQSPATLSVSPGERATLSCRASQSVSSN				
		Section 2			
		54	60	70	80
L2	(54) RATGIPARFSGSGSGTEFTLTISIQLQSEDFAVYYCQQYNNWP				90
A15-6.12_LC	(54) RATGIPARFSGSGSGTEFTLTISIQLQSEDFAVYYCQQYNNWP				
Consensus	(54) RATGIPARFSGSGSGTEFTLTISIQLQSEDFAVYYCQQYNNWP				
		Section 3			
		107	107		
L2	(96) -				
A15-6.12_LC	(107) K				
Consensus	(107)				

positives: 86.9%	identity: 85.0%
------------------	-----------------

FIG. 29

	Section 1			Section 2			Section 3		
	1	10	20	30	40	53			
A15-6.2 HC	(1)	QVQLQESGPGLVVKPSETLSILTCTVSGGSISTYYWNSWIRQPPGKGLEWIGYIYY							
VH4-59	(1)	QVQLQESGPGLVVKPSETLSILTCTVSGGSISYYWNSWIRQPPGKGLEWIGYIYY							
Consensus	(1)	QVQLQESGPGLVVKPSETLSILTCTVSGGSISYYWNSWIRQPPGKGLEWIGYIYY							
	54	60	70	80	90	90			
A15-6.2 HC	(54)	TGNTYYNPNSLKSRLVTSVDTTSKRNQFSIILKLN							
VH4-59	(54)	SGSSDNYNPNPSLKSRLVTSVDTTSKRNQFSIILKLN							
Consensus	(54)	SG T YNPSLKSRLVTSVDTTSKRNQFSIILK LN							
	107	121							
A15-6.2 HC	(107)	AFDIWQGQTMVSVSS							
VH4-59	(98)								
Consensus	(107)								

positives: 77.7%	identity: 75.2%
------------------	-----------------

FIG. 30

		Section 1					
		10	20	30	40	50	54
A15-6.2_LC	(1)	DIVMTQSPSPLPV	IPGE PASISCRSSQSLI	LSNG NGN NYLQKPGQSPQLIY			
(1)	DIVMTQSPSPLPV	IPGE PASISCRSSQSLI	HSNG Y NYLQKPGQSPQLIY				
A19	(1)	DIVMTQSPSPLPV	IPGE PASISCRSSQSLI	SNG NYLDWYLQKPGQSPQLIY			
Consensus	(1)	DIVMTQSPSPLPV	PGE PASISCRSSQSLI				
		Section 2					
		55	60	70	80	90	108
A15-6.2_LC	(55)	LGSNRASGVVPDRF	SGSGSGT	DDVCG	YYCMQALQI	IPLTFGGGTK	
(55)	LGSNRASGVVPDRF	SGSGSGT	DDVCG	YYCMQALQI	IPLTFGGGTK		
A19	(55)	LGSNRASGVVPDRF	SGSGSGT	DDVCG	YYCMQALQI	IPLTFGGGTK	
Consensus	(55)	LGSNRASGVVPDRF	SGSGSGT	DDVCG	YYCMQALQI	IPLTFGGGTK	
		Section 3					
A15-6.2_LC	(109)	109	112				
(109)	VEIK						
A19	(101)	---					
Consensus	(109)						

positives: 85.7%	identity: 83.9%
------------------	-----------------

FIG. 31

		Section 1			
		10	20	30	40
A15-6.9 HC	(1) QVYQI	LEQSGPGLVVKPSE	TLCTVSGGSISSG	TYWMSWIROHPGR	GLEWIGYI
VH4-31	(1) QMQLQES	GPGLVVKPSQTL	TLCTVSGGSISSG	YXWMSWIROHPGK	GLEWIGYI
Consensus	(1) QVQL	SGPGLVVKPS	TLSLTCTVSGGSISSG	YYWSWIROHPGK	GLEWIGYI
		Section 2			
		50	60	70	80
A15-6.9 HC	(54) YYSGSTYHNP	PSLKSRLTISVDT	SKNOFSIKLSSVTA	ADTAVYYCAR	GGDGYRY
VH4-31	(54) YYSGSTYHNP	SLKSRLTISVDT	SKNOFSIKLSSVTA	ADTAVYYCAR	-----
Consensus	(54) YYSGSTYHNP	SLKSRLTISVDT	SKNOFSIKLSSVTA	ADTAVYYCAR	-----
		Section 3			
		90	100	110	106
A15-6.9 HC	(107) 107	WGQGTLVTVSS	-----	-----	-----
VH4-31	(107)	(100)	-----	-----	-----
Consensus	(107)				

positives: 81.2%	identity: 77.8%
------------------	-----------------

FIG. 32

positives: 86.9% identity: 85.0%

FIG. 33

		Section 1			Section 2			Section 3		
		10	20	30	40	50	60	70	80	90
A15-6.11_HC	(1)	QVQLQESGPGLVVKPSQTLSSLTCTVSGGSISSGGT								
VH4-31	(1)	QVQLQESGPGLVVKPSQTLSSLTCTVSGGSISSGGT								
Consensus	(1)	QVQLQESGPGLVVKPSQTLSSLTCTVSGGSISSGGT								
A15-6.11_HC	(54)	YYSGSTYYNPSLKSRSVTISVDTTSKNQFSLKLSSVTAADTA								
VH4-31	(54)	YYSGSTYYNPSLKSRSVTISVDTTSKNQFSLKLSSVTAADTA								
Consensus	(54)	YYSGSTYYNPSLKSRSVTISVDTTSKNQFSLKLSSVTAADTA								
A15-6.11_HC	(107)	WGGQGTIVTVSS								
VH4-31	(107)	WGGQGTIVTVSS								
Consensus	(107)	WGGQGTIVTVSS								

positives: 83.8%	identity: 82.9%
------------------	-----------------

FIG. 34

		Section 1			Section 2			Section 3			
		10	20	30	40	50	60	70	80	90	106
A15-6.11_LC	(1)	ETIVMTQSPATLSVSPGERATLSCRASOSVSNINLAWYQQKPGQAPRLLIYGAST									
L2	(1)	ETIVMTQSPATLSVSPGERATLSCRASOSVSNINLAWYQQKPGQAPRLLIYGAST									
Consensus	(1)	ETIVMTQSPATLSVSPGERATLSCRASOSVSNINLAWYQQKPGQAPRLLIYGAST									
A15-6.11_LC	(54)	RATGIPARFSGSGSGTTEFTLTISLQSEDFAVYYCQQYNNNW									
L2	(54)	RATGIPARFSGSGSGTTEFTLTISLQSEDFAVYYCQQYNNNW									
Consensus	(54)	RATGIPARFSGSGSGTTEFTLTISLQSEDFAVYYCQQYNNNW									
A15-6.11_LC	(107)	107									
L2	(107)	K									
Consensus	(107)	-									

positives: 87.9%	identity: 87.9%
------------------	-----------------

FIG. 35

USE OF ANTIBODIES AGAINST THE MUC18 ANTIGEN

Bar-Eli, et al.

Appl. No.: 10/660,357 Atty Docket: ABGENIX.030C1

36 / 36

Clone #	VH	#del	VH End	#N's	N Sequence	DH	Size of D	D Sequence	#N's	N Sequence	JH	#del	JH Segment
A15-3.10	DP-71/4-59	0	GAGAGA	8	TCAGGGGC	D21-9	8	AGTGGTTA	7	CTACCCG	JH3B	0	ATGCTT
A15-3.22	DP-65/4-31	0	GAGAGA	9	GGGAGATGG	-	-	-	-	-	JH4B	-4	CTTGA
A15-3.27	DP-71/4-59	0	GAGAGA	8	TCAGGGGC	D21-9	8	AGTGGTTA	7	CTACCCG	JH3B	0	ATGCTT
A15-3.45	DP-14/1-18	0	GAGAGA	6	AACTAA	D3-10	12	GGTTCGGGGAGT	2	CC	JH6B	-9	ACTACT
A15-3.65	DP-65/4-31	0	GAGAGA	8	TCGGGAAA	D6-13	8	CAGCTGGT	4	TTTT	JH5A	-11	GAATAC
A15-6.1	DP-49/3-30	3	GAGAGA	1	T	D3-3	18	CGATTTTGGAGTGGTTA	3	TCG	JH6B	-12	ACTACG
A15-6.2	DP-71/4-59	0	GAGAGA	7	TCCAGGGC	D6-19	11	CAGTGGCTGGT	5	CCTG	JH3B	0	ATGCTT
A15-6.9	DP-65/4-31	1	CGAGAG	3	GGG	D5-24	11	GAGATGGCTAC	4	AGAT	JH1	-16	ACTGGG
A15-6.11	DP-65/4-31	1	CGAGAG	3	GGG	D5-24	13	GAGATGGCTACAA	2	GT	JH1	-16	ACTGGG
A15-6.12	DP-65/4-31	1	CGAGAG	3	GGG	D5-24	11	GAGATGGCTAC	4	AGAT	JH1	-16	ACTGGG

Clone #	VK	#del	VH End	#N's	N Sequence	JK	#del	JK end
A15-3.10	02/012/DPK	0	CCCTCC	9	GGAGTGCAG	JK2	-7	TTTGG
A15-3.22	A30	3	TTACCC	0	0	JK4	0	GCTCAC
A15-3.27	A30	3	TTACCC	0	0	JK1	0	GTGGAC
A15-3.45	B3/DPK24	1	TCCCTC	3	GGT	JK1	-5	CGTTCG
A15-3.65	08/018/DPK	1	TCCCTC	0	0	JK4	-2	TCACTTC
A15-6.1	A20/DPK4	3	GTCCCC	0	0	JK3	0	ATTCAC
A15-6.2	A3/A19/DPK	1	TTCCCTC	0	0	JK4	-2	TCACTTC
A15-6.9	L2/DPK21	1	GGCCTC	0	0	JK1	-2	GGACGTT
A15-6.11	L2/DPK21	1	GGCCTC	0	0	JK1	-2	GGACGTT
A15-6.12	L2/DPK21	1	GGCCTC	0	0	JK1	-2	GGACGTT

F/G. 36